Publications by authors named "M Bagot"

638 Publications

Analysis of T cell responses directed against the spike and/or membrane and/or nucleocapsid proteins in chilblain-like lesions patients during the COVID-19 pandemic.

Br J Dermatol 2021 Jul 14. Epub 2021 Jul 14.

Université de Paris, Human immunology Pathophysiology Immunotherapy, INSERM U976, Institut de Recherche Saint-Louis, F-75010, Paris, France.

A range of cutaneous manifestations has been described in association with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) infection during the coronavirus disease 2019 (COVID-19) pandemic . Among them, chilblain like lesions (CLL) occurred more frequently than expected. A direct link was demonstrated thanks to the visualization of viral particles in the skin endothelial cells by electron microscopy which was further questioned . An indirect link was highlighted with high prevalence of seropositivity in CLL patients compared to general population .
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20647DOI Listing
July 2021

Male genital lichen planus: A retrospective study of 89 cases.

Ann Dermatol Venereol 2021 Jul 1. Epub 2021 Jul 1.

Dermatology Department, Saint-Louis University Hospital, AP-HP, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address:

Background: Unlike other types of lichen planus (LP), there are no series concerning male genital LP.

Objective: To describe the clinical characteristics, diagnosis, and response to treatment of male genital LP.

Patients And Methods: A retrospective study of male patients with genital LP consulting a dermatologist specialized in anogenital diseases between January 2010 and 2019. Demographic data, history, functional signs, clinical characteristics, pathology, complications, and treatment efficacy were collected.

Results: Eighty-nine patients were included at four centers. The median age was 51 years. Most patients were uncircumcised and asymptomatic. In 88.8% of cases, only the genital mucosa was involved. Erythema (71%), papules (21.3%), lacy network (15.7%), atrophic lesions (15.7%), erosions (14.6%), and post-inflammatory hyperpigmentation (2.2%) were less frequently observed. Biopsy results confirmed LP in 61.3% of cases but could not rule out other inflammatory genital dermatoses in other cases. Anatomic complications were observed in 30.3% of patients. Topical corticosteroids (TCS) induced remission in most cases. Tacrolimus efficacy was comparable to that of TCS.

Conclusion: Male genital LP is a rare inflammatory disorder chiefly affecting uncircumcised men. It is found predominantly on the mucosal component of the penis and presents as non-erosive inflammatory balanitis in most cases, with frequent partial or complete remission on treatment with TCS.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2021.04.007DOI Listing
July 2021

Health and economic burden estimates of snakebite management upon health facilities in three regions of southern Burkina Faso.

PLoS Negl Trop Dis 2021 Jun 21;15(6):e0009464. Epub 2021 Jun 21.

The Centre for Snakebite Research & Interventions, Department of Tropical Disease Biology, Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

Background: Snakebite has become better recognized as a significant cause of death and disability in Sub-Saharan Africa, but the health economic consequences to victims and health infrastructures serving them remain poorly understood. This information gap is important as it provides an evidence-base guiding national and international health policy decision making on the most cost-effective interventions to better manage snakebite. Here, we assessed hospital-based data to estimate the health economic burden of snakebite in three regions of Burkina Faso (Centre-Ouest, Hauts Bassins and Sud-Ouest).

Methodology: Primary data of snakebite victims admitted to regional and district health facilities (eg, number of admissions, mortality, hospital bed days occupied) was collected in three regions over 17 months in 2013/14. The health burden of snakebite was assessed using Disability-Adjusted Life Years (DALYs) calculations based upon hospitalisation, mortality and disability data from admitted patients amongst other inputs from secondary sources (eg, populations, life-expectancy and age-weighting constants). An activity-based costing approach to determine the direct cost of snake envenoming included unit costs of clinical staff wages, antivenom, supportive care and equipment extracted from context-relevant literature.

Findings: The 10,165 snakebite victims admitted to hospital occupied 28,164 hospital bed days over 17 months. The annual rate of hospitalisation and mortality of admitted snakebite victims was 173 and 1.39/100,000 population, respectively. The estimated annual (i) DALYs lost was 2,153 (0.52/1,000) and (ii) cost to hospitals was USD 506,413 (USD 49/hospitalisation) in these three regions of Burkina Faso. These costs appeared to be influenced by the number of patients receiving antivenom (10.90% in total) in each area (highest in Sud-Ouest) and the type of health facility.

Conclusion: The economic burden of snake envenoming is primarily shouldered by the rural health centres closest to snakebite victims-facilities that are typically least well equipped or resourced to manage this burden. Our study highlights the need for more research in other regions/countries to demonstrate the burden of snakebite and the socioeconomic benefits of its management. This evidence can guide the most cost-effective intervention from government and development partners to meet the snakebite-management needs of rural communities and their health centres.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1371/journal.pntd.0009464DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248599PMC
June 2021

Multicentric EORTC retrospective study shows efficacy of Brentuximab Vedotin in Μycosis Fungoides and Sezary Syndrome patients with variable CD30 positivity.

Br J Dermatol 2021 Jun 16. Epub 2021 Jun 16.

Department of Dermatology, Centre for Rare Diseases, University Hospital Birmingham, Birmingham, UK.

Background: Brentuximab Vedotin (BV) was approved as therapy for Mycosis Fungoides (MF) based on ALCANZA trial. Since then few real-life data are available.

Objective: The aim of this study was to evaluate efficacy and safety of BV in MF/Sezary Syndrome (SS) patients with variable CD30 positivity in real life cohort and explore potential predictors.

Methods: Data from 72 MF/SS patients across 9 EORTC (European Organization for Research and Treatment of Cancer) centers were included. The primary endpoint was to evaluate the proportion of patients with: overall response (ORR), ORR lasting over four months (ORR4), time to response (TTR), response duration (RD), progression free survival (PFS) and time to next treatment (TTNT). Secondary aims included safety evaluation and association of clinicopathological features with ORR, RD and TTNT.

Findings: Seventy-two patients were included; all had received at least one systemic treatment. ORR was achieved in 45/67; ORR4 in 28/67 with median TTR 8 weeks (IQR 5.5-14) and median RD 9 months (IQR 3.4-14). Median PFS was 7 months (IQR 2-12) and median TTNT 30 days (6-157.5). Patients' response, RD, PFS and TTNT were not associated with any clinicopathological characteristics. In MF group, patients with stage IIB/III versus IV achieved longer PFS and higher percentage of ORR4. There was statistically significant association between LCT and skin ORR (p=0.03). ORR4 was more frequently achieved in patients without lymph node involvement (p=0.04).

Conclusions: BV is an effective option for MF/SS patients including those with variable CD30 positivity, LCT, SS, longer disease duration and highly pretreated.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20588DOI Listing
June 2021

Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases.

Br J Dermatol 2021 Jun 15. Epub 2021 Jun 15.

Dermatology department, AP-HP, Henri Mondor hospital, Créteil, France.

The prognosis of erythrodermic cutaneous T-cell lymphomas (ECTL) depends upon lymph node (N), visceral (M) involvement, and blood stage (B, i.e circulating Sézary cells, identified upon peripheral blood immunophenotyping, B0: absolute count <250/mm , B1: 250-1000/mm , and B2 stage, Sézary syndrome: ≥1000/mm ) with a 5-year overall survival of 36% for Sézary syndrome, the most common subtype of ECTL. Other prognostic markers include male sex, age >60 years, an elevated rate of lactate dehydrogenase (LDH), and histologic large-cell transformation (LCT). ECTL progression is usually homogeneous and simultaneously involves all compartments of the disease. We report nine patients with B1 or B2 ECTL displaying an unusually discrepant outcome profile with the rapid onset of N or M involvement contrasting with the lack of progression of cutaneous and blood involvement.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.20580DOI Listing
June 2021